{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"CR rate at the end of randomized regimen per investigator was defined as the percentage of participants who achieved CR at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by IRF. CR was defined as disappearance of all evidence of disease.","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"NUMBER","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of randomized regimen (approximately 1 year)","title":"Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF","type":"SECONDARY","unitOfMeasure":"percentage of participants"}